1. GPCR/G Protein
  2. Angiotensin Receptor

Angiotensin Receptor

Angiotensin receptors are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. AT2 receptors are more plentiful in the fetus and neonate. Other poorly characterized subtypes include the AT3 and AT4 receptors.

Angiotensin Receptor Related Products (53):

Cat. No. Product Name Effect Purity
  • HY-13948
    Angiotensin II human Modulator 99.96%
    Angiotensin II human is a vasoconstrictor that acts on the AT1 and the AT2 receptor.
  • HY-17512A
    Losartan potassium Antagonist 99.91%
    Losartan (potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
  • HY-17512
    Losartan Antagonist 99.24%
    Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
  • HY-15778
    AVE 0991 Agonist 99.16%
    AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC50 of 21 nM.
  • HY-12403
    Angiotensin 1-7 Inhibitor 99.61%
    Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC50 of 0.65 μM.
  • HY-102093
    ZD 7155(hydrochloride) Antagonist
    ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.
  • HY-P1515A
    Angiotensin II (3-8), human TFA Agonist 98.99%
    Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT1 receptor.
  • HY-P1564
    [Sar1, Ile8]-Angiotensin II
    [Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
  • HY-B0195
    Tranilast Inhibitor 99.60%
    Tranilast is an antiallergic agent.
  • HY-13955
    Telmisartan Antagonist 99.96%
    Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
  • HY-10259A
    PD 123319 ditrifluoroacetate Antagonist 99.76%
    PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
  • HY-18204
    Valsartan Antagonist 99.35%
    Valsartan (CGP-48933) is an angiotensin II receptor antagonist for treatment of high blood pressure and heart failure.
  • HY-P0216
    A 779 Antagonist >98.0%
    A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII. Sequence: Asp-Arg-Val-Tyr-Ile-His-d-Ala.
  • HY-18204A
    LCZ696 Inhibitor 99.96%
    LCZ696 is a dual angiotensin II receptor and neprilysin inhibitor.
  • HY-12405
    CGP-42112 Antagonist 98.82%
    CGP-42112(CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist.
  • HY-17004
    Olmesartan Antagonist 99.01%
    Olmesartan is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.
  • HY-13106
    EMA401 Antagonist 98.52%
    EMA401, a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.
  • HY-B0205
    Candesartan Antagonist
    Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
  • HY-17505
    Candesartan Cilexetil Antagonist >98.0%
    Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
  • HY-B0780
    Fimasartan Antagonist 98.77%
    Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.